Cervical Cancer Clinical Trial
Official title:
Adjuvant Chemotherapy Versus Observation After Radiation With Concurrent Cisplatin of Cervical Cancer (With Pelvic or Para-aortic Node Involvement) :A Phase 3 Prospective Multi-institutional Randomised Controlled Trial
Cervical cancer with pelvic or para-aortic node involvement has a poor prognosis. Despite low-quality data, the routine practice to treat these patients is radiation with concurrent cisplatin. The aim of this study is to compare systemic chemotherapy with observation after radiation with concurrent cisplatin of cervical cancer ( with pelvic or para-aortic node involvement) for incidence of adverse events and local recurrence rate.
1. Background Cervical Cancer is one of the most common malignant tumors of Chinese
females. Women with evidence of para-aortic node involvement have a poor prognosis with
a five-year survival rate of approximately 40 percent. Despite low-quality data, the
routine practice to treat these patients is radiation with concurrent cisplatin. It is
not clear whether systemic chemotherapy delivered following RT will obtain survival
benefit.
2. Objective The aim of this study is to compare systemic chemotherapy with observation
after radiation with concurrent cisplatin of cervical cancer ( with pelvic or
para-aortic node involvement) for incidence of adverse events, 3y-PFS and 5y-OS, .
3. Patients
A patient will be enrolled when patient have:
1. Pathologically diagnosed cervical cancer;
2. pelvic or para-aortic lymph metastases, at least match one of following
- CT or MRI scan shows pelvic or para-aortic node with a minimal axial diameter
diameter ≥ 7mm in the largest plane
- pelvic or para-aortic lymph node shows necrosis or extra capsular spread
- PET/CT scan finds positive pelvic or para-aortic node lymph node
- biopsy confirms lymph metastase
3. Stage IB1-IVA diseases (FIGO system ver. 2014) without treatment before;
4. Karnofsky Performance Scores ≥ 70;
4.Method
1. Randomization is performed to divide the patients into the control group (Group A) and
the experimental group (Group B). In Group A, observation is given after radiation with
concurrent cisplatin. But in Group B, three cycles of adjuvant chemotherapy ( Paclitaxel
plus Cisplatin) are administered after radiation with concurrent cisplatin. The regimen
of adjuvant chemotherapy following radiation is Paclitaxel 135mg/m2 plus Cisplatin
60mg/m2 once 3 weeks.The Grade 3/4 adverse events (CTCAE criteria ver. 4.03), the 3-year
progression-free survival of the 2 groups, the 5-year overall survival of the 2 groups
are compared.
2. In Group A and Group B, both the radiation method and the regimen of concurrent
chemotherapy are the same.The gross tumor volume (GTVnd) is the lymph node lesion and
given a dose of 60Gy. The clinical target volume (CTV) is according to the lymph
drainage pathway and given a dose of 45Gy. The regimen of concurrent chemotherapy is
Cisplatin 80mg/m2 once three weeks.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06223308 -
A Study Evaluating the Safety and Efficacy of HB0028 in Subjects With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Terminated |
NCT03367871 -
Combination Pembrolizumab, Chemotherapy and Bevacizumab in Patients With Cervical Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT04537156 -
Efficacy, Immunogenicity and Safty Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,58 Type)(E.Coli)
|
Phase 3 | |
| Recruiting |
NCT03668639 -
Safety and Antiemetic Efficacy of Akynzeo Plus Dexamethasone During Radiotherapy and Concomitant Weekly Cisplatin
|
Phase 2/Phase 3 | |
| Active, not recruiting |
NCT04242199 -
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors
|
Phase 1 | |
| Withdrawn |
NCT04806945 -
A Phase III Study to Evaluate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy in Patients With Advanced Cervical Cancer
|
Phase 3 | |
| Active, not recruiting |
NCT04185389 -
Long-Term Follow-Up of HPV FOCAL Participants
|
||
| Withdrawn |
NCT03007771 -
Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) Used for Mild Hyperthermia
|
Phase 1 | |
| Completed |
NCT03384511 -
The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies.
|
Phase 4 | |
| Recruiting |
NCT05107674 -
A Study of NX-1607 in Adults With Advanced Malignancies
|
Phase 1 | |
| Completed |
NCT05120167 -
Strategies for Endocervical Canal Investigation in Women With Abnormal Screening Cytology and Negative Colposcopy
|
N/A | |
| Recruiting |
NCT05483491 -
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
|
Phase 1 | |
| Recruiting |
NCT05736588 -
Elimisha HPV (Human Papillomavirus)
|
N/A | |
| Completed |
NCT05862844 -
Promise Women Project
|
N/A | |
| Recruiting |
NCT04934982 -
Laparoscopic or Abdominal Radical Hysterectomy for Cervical Cancer(Stage IA1 With LVSI, IA2)
|
N/A | |
| Recruiting |
NCT03876860 -
An Enhanced Vaginal Dilator to Reduce Radiation-Induced Vaginal Stenosis
|
N/A | |
| Completed |
NCT03652077 -
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies
|
Phase 1 | |
| Completed |
NCT00543543 -
Broad Spectrum HPV (Human Papillomavirus) Vaccine Study in 16-to 26-Year-Old Women (V503-001)
|
Phase 3 | |
| Terminated |
NCT04864782 -
QL1604 Plus Chemotherapy in Subjects With Stage IVB, Recurrent, or Metastatic Cervical Cancer
|
Phase 2/Phase 3 | |
| Recruiting |
NCT04226313 -
Self-sampling for Non-attenders to Cervical Cancer Screening
|
N/A |